Targeted, safe, long-lasting retinal treatments

Oxular is transforming the treatment of retinal disorders to improve patients’ vision so they can live better lives.

Targeted, safe, long-lasting retinal treatments

Oxular is transforming the treatment of retinal disorders to improve patients’ vision so they can live better lives.

Latest News

IND clearance for OXU-001

We are thrilled to announce the IND

Oxular at Dry AMD Conference

Oxular’s CMO, Friedrich Asmus, MD, spoke at the

New Oxular CBO – James Jogerst

OXFORD, UK – November 7, 2022 –

Oxular Sponsors ISU 2022

Oxular is thrilled to sponsor ISU 2022

Latest News

Oxular's innovative technology...

Targeted, routine suprachoroidal delivery

Long-lasting treatments

...transforms the treatment paradigm…

...to offer novel approaches for retinal specialists and meaningful benefits for patients.

Best-in-class or first-in-class treatments
Sustained treatment benefits, leading to fewer injections and better patient outcomes and adherence
Better safety through targeted drug delivery with enriched choroidal-retinal exposure
Reduced treatment burden and related costs for healthcare systems

Putting innovation into action

Targeted, routine, suprachoroidal delivery		Long-lasting treatments
Oxulumis®		Oxuspheres™



	Pipeline programs
High prevalence retinal disorders
Diabetic macular edema (DME), retinal vein occlusion (RVO), uveitis Diabetic retinopathy
	Future opportunities
Indications		Modalities
Geographic atrophy / intermediate AMD Neovascular AMD Uveal melanoma Neuroprotection Front-of-eye		Small molecules AAV gene therapies Peptides/proteins Antibodies siRNA

Building a leading retinal therapeutics franchise

Oxular is committed to transforming the treatment paradigm for sight-threatening retinal disorders by providing safe, durable therapeutics that are precisely delivered to specific ocular tissues to control disease activity.

We have…